ADMA Biologics (ADMA)
Manufactures plasma-derived immune globulins for primary immune deficiency and hepatitis B exposure.
Something off on this page? Send us feedback.
Manufactures and markets ASCENIV and BIVIGAM intravenous immune globulins for primary humoral immunodeficiency, plus Nabi-HB for specified hepatitis B exposures. Most revenue comes from ASCENIV; an FDA-licensed Boca Raton plant, seven owned plasma centers, and contracted third-party supply support production.
Manufactures and markets ASCENIV and BIVIGAM, intravenous immune globulins for primary humoral immunodeficiency, and Nabi-HB, a hepatitis B immune globulin for specified exposures. ASCENIV, the principal commercial product, uses patented donor screening and tailored plasma pooling to incorporate high-titer antibodies against respiratory syncytial virus.
BioManufacturing handles fractionation, purification, fill-finish, commercialization, and development at an FDA-licensed facility in Boca Raton, Florida. Plasma Collection Centers operates seven FDA-licensed U.S. centers, supplying internal production and selling some source and hyperimmune plasma to third parties.
Most revenue comes from ASCENIV, and customer concentration is high. Manufacturing depends on continued FDA cGMP compliance at the Boca Raton site and reliable high-titer plasma supply from owned centers and contracted third parties.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 15, 2026 | Mizuho Securities | Target | Target: $24 | Target: $17 |
| Jun 10, 2026 | Raymond James | Target | Target: — | Target: $21 |
| May 7, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $21 | Target: $18 |
| Apr 20, 2026 | Canaccord Genuity | Target | Target: — | Target: $21 |
| Apr 13, 2026 | Mizuho Securities | Target | Target: $14 | Target: $24 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $136.0M · Total debt $203.8M · Total assets $684.2M · Shareholders' equity $408.2M
- Revenue
- $124.4M
- Operating income
- $52.4M
- Net income
- $37.8M
No dividends on record.
| Institutions | 91.70% | 205.39M shares | |
|---|---|---|---|
| 341 holders · as of Jun 30, 2026 | |||
| Insiders | 0.85% | 1.90M shares | |
| 9 holders · as of Jul 28, 2026 | |||
| Strategic holders | 5.33% | 11.93M shares | |
| 1 holder · as of Feb 15, 2022 | |||
| Other | 2.12% | 4.76M shares | |
| remainder | |||
223.98M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 17.12% | 38.36M | as of Jun 30, 2026 |
State Street CorpInstitution | 7.64% | 17.12M | as of Jun 30, 2026 |
Perceptive Advisors LLC1Strategic10 percent owner | 5.33% | 11.93M | filed Feb 15, 2022 |
NWQ Investment Management Company, LLCInstitution | 4.74% | 10.61M | filed Feb 11, 2022 |
Vanguard Capital Management LLCInstitution | 4.51% | 10.10M | as of Jun 30, 2026 |
- Perceptive Advisors LLC's own ownership statement (13G/A, Feb 15, 2022) reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 27, 2026 | Jerrold B. Grossman | director | +6,400 | $7.91 |
| May 12, 2026 | Jerrold B. Grossman | director | +12,500 | $8.01 |
| May 11, 2026 | Jerrold B. Grossman | director | +12,500 | $8.01 |
| Mar 16, 2026 | Adam S. Grossman | director, officer: President and CEO | −21,000 | $15.16 |
| Mar 9, 2026 | Kaitlin M. Kestenberg-Messina | officer: COO and SVP, Compliance | −10,096 | $15.63 |
- Takeda (ADR)
Largest plasma-derived therapies franchise; Gammagard and HYQVIA lead IG share
- Grifols (ADR)
Spanish plasma major; Flebogamma / Gamunex IVIG, Xembify SCIG, HyperHEP B
- Kamada
Specialty hyperimmune Ig maker; HEPAGAM B and CYTOGAM contest hyperimmune turf
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ADMA Biologics | $9.53 | −2.91% | $2.27B | 14.0 | 11.9 | 4.4 | +2.0% |
| Takeda (ADR) | $18.84 | −0.61% | $60.30B | 52.9 | 60.0 | 2.0 | +4.2% |
| Grifols (ADR) | $7.28 | −2.22% | $6.29B | 9.7 | — | 0.7 | −1.8% |
| Kamada | $8.73 | −1.63% | $511.7M | 23.4 | 17.3 | 2.7 | +22.7% |
| Median | 23.4 | 38.6 | 2.0 | +4.2% |